Oruka Therapeutics (NASDAQ:ORKA) Hits New 1-Year Low – Time to Sell?

Oruka Therapeutics, Inc. (NASDAQ:ORKA)’s share price reached a new 52-week low during trading on Tuesday . The stock traded as low as $18.23 and last traded at $18.33, with a volume of 7234 shares. The stock had previously closed at $18.51.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Oruka Therapeutics in a research report on Monday. Wedbush reissued an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. Leerink Partners assumed coverage on Oruka Therapeutics in a research report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price target on the stock. Jefferies Financial Group assumed coverage on Oruka Therapeutics in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price target on the stock. Finally, TD Cowen assumed coverage on Oruka Therapeutics in a research report on Monday, September 16th. They set a “buy” rating on the stock. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Stock Up 8.4 %

The company has a market capitalization of $709.08 million, a PE ratio of -3.24 and a beta of 0.87. The business’s fifty day simple moving average is $25.76.

Institutional Trading of Oruka Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC acquired a new stake in Oruka Therapeutics in the third quarter valued at $343,000. The Manufacturers Life Insurance Company acquired a new stake in Oruka Therapeutics in the third quarter valued at $1,037,000. Wellington Management Group LLP acquired a new stake in Oruka Therapeutics in the third quarter valued at $2,013,000. Janus Henderson Group PLC acquired a new stake in Oruka Therapeutics in the third quarter valued at $5,840,000. Finally, Redmile Group LLC acquired a new stake in Oruka Therapeutics in the third quarter valued at $10,091,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.